Drugs and Devices

June 2017 Vol. 12 No. 6

Researchers have developed a rapid screening method to identify beneficial pairs of existing FDA-approved drugs to combat multi-drug resistant bacterial infections, according to a study in PLoS Biology. Read more and access the study . . .

June 2017 Vol. 12 No. 6

On June 13, the U.S. Food and Drug Administration (FDA) announce new steps it is taking to address opioid addiction.
Opioid formulations with properties designed to deter abuse are not abuse-proof or addiction-proof. These drugs can still be abused, particularly orally, and their use can still lead . . .

June 2017 Vol. 12 No. 6

Use of statins is associated with a higher risk for Parkinson’s disease, according to a study in Movement Disorders. 
Objective
Using a large U.S. claims database (MarketScan), we investigated the controversy surrounding the role of statins in Parkinson’s disease (PD).

Statins may facilitate Parkinson’s disease: Insight . . .

June 2017 Vol. 12 No. 6

Expanded use approval relies on real world evidence

The U.S. Food and Drug Administration today approved an expanded indication for the Sapien 3 Transcatheter Heart Valve (THV) for patients with symptomatic heart disease due to failure of a previously placed bioprosthetic aortic or mitral valve whose risk of death . . .

May 2017 Vol. 12 No. 5

On May 30, the U.S. Food and Drug Administration (FDA) approved the first generic versions of Strattera (atomoxetine) to treat attention-deficit/hyperactivity disorder (ADHD) in pediatric and adult patients. Read more . . .

May 2017 Vol. 12 No. 5

Children who participated in the PROSPER (PROmoting School-community-university Partnerships to Enhance Resilience) program over seven years ago showed lower rates of substance abuse after high school graduation, according to a new study conducted by researchers from Penn State and Iowa State Universities

PROSPER, a community-based preventive intervention . . .

May 2017 Vol. 12 No. 5

On May 5, the U.S. Food and Drug Administration (FDA) approved Radicava (edaravone) to treat patients with amyotrophic lateral sclerosis (ALS). Read more . . .

April 2017 Vol. 12 No. 4

On April 27, the U.S. Food and Drug Administration (FDA) expanded the approved use of Stivarga (regorafinib) to include treatment of patients with hepatocellular carcinoma who have been previously treated with the drug sorafenib. It’s the first FDA-approved treatment for a liver cancer in almost a decade . . .

April 2017 Vol. 12 No. 4

Administering medications intranasally as an alternative to I.V.s and injections is becoming more frequent in the ED and out-of-hospital settings, according to a study in Annals of Emergency Medicine. Read more . . .